Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease
- 1 July 2015
- journal article
- Published by Elsevier in Neuroscience Letters
- Vol. 599, 115-119
Abstract
No abstract availableKeywords
Funding Information
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z111107058811012)
- High Level Technical Personnel Training Project of Beijing Health System (2011-3-022)
- Beijing Nature Science Foundation and Municipal Commission of Education (kz20120025028)
- National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2013BAI09B03)
- Beijing Institute For Brain Disorders (BIBD-PXM2013_014226_07_000084)
This publication has 27 references indexed in Scilit:
- Neurodegenerative changes initiated by presynaptic dysfunctionTranslational Neurodegeneration, 2013
- Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in NeurodegenerationJournal of Parkinson’s Disease, 2013
- α-Synuclein in Parkinson disease and other neurodegenerative disordersClinical Chemistry and Laboratory Medicine (CCLM), 2011
- The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part IJournal of Neuropathology & Experimental Neurology, 2007
- Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's diseaseThe FASEB Journal, 2006
- α‐Synuclein induces apoptosis by altered expression in human peripheral lymphocytes in Parkinson’s diseaseThe FASEB Journal, 2004
- Parkinson's diseaseThe Lancet, 2004
- Neuropathological spectrum of synucleinopathiesMovement Disorders, 2003
- α-Synuclein in Lewy bodiesNature, 1997
- What features improve the accuracy of clinical diagnosis in Parkinson's diseaseNeurology, 1992